Sintilimab

Adimab Provides 2022 Update on Clinical Pipeline

Retrieved on: 
Wednesday, January 11, 2023

This brings the total number of Adimab partner programs that have entered the clinic to 62.

Key Points: 
  • This brings the total number of Adimab partner programs that have entered the clinic to 62.
  • Partners have recently filed for BLA approval on three additional programs and another three programs are currently in pivotal trials.
  • “Over the last five years alone, partners have initiated clinical trials for 52 new programs.
  • Bispecifics and T-cell engagers: Adimab has extensive bispecific and multispecific capabilities, including common light chain and fragment-based discovery and engineering.

Innovent Announced Clinical Data of Multiple Trials Will be Presented at the 2022 ESMO-IO and ASH Annual Meetings

Retrieved on: 
Monday, November 28, 2022

On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.

Key Points: 
  • On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
  • Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
  • An additional 2 assets are under NMPA NDA review, 5 assets are in Phase 3 or pivotal clinical trials, and 20 more molecules are in clinical studies.
  • Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts.

Innovent Announces First Patient Dosing in Australia in Phase 1 Study of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) in Patients with Advanced Malignancies

Retrieved on: 
Wednesday, August 24, 2022

Dr. Hui Zhou, Senior Vice President of Innovent,stated:"Most patients will develop primary or secondary resistance after treatments of immune checkpoint inhibitors.

Key Points: 
  • Dr. Hui Zhou, Senior Vice President of Innovent,stated:"Most patients will develop primary or secondary resistance after treatments of immune checkpoint inhibitors.
  • We are looking forward to the positive results of IBI363 in patients with advanced solid tumors or lymphoma.
  • IBI363 is our first molecule to initiate clinical study in Australia, which marks a solid step of Innovent's global innovation strategy.
  • Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts.

HUTCHMED Highlights Fruquintinib MRCT FRESCO-2 Data to be Presented at the Upcoming ESMO Congress 2022

Retrieved on: 
Tuesday, August 23, 2022

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 23, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that initial results of the multi-regional clinical trial (“MRCT”) of fruquintinib, FRESCO-2, will be presented at the upcoming European Society for Medical Oncology (“ESMO”) Congress 2022, taking place on September 9-13, 2022. The meeting will be held at the Paris Expo Porte de Versailles, in Paris, France.

Key Points: 
  • Details of the conference call dial-in and the webcast link will be provided on the company website at www.hutch-med.com/event/ .
  • In addition to OS, a statistically significant improvement in progression-free survival (PFS), a key secondary endpoint, was observed.
  • The safety profile of fruquintinib in FRESCO-2 was consistent with previously reported studies.
  • Fruquintinib was designed to improve kinase selectivity to minimize off-target toxicities, improve tolerability and provide more consistent target coverage.

Insilico Medicine Appoints Sujata Rao, M.D., as Senior Vice President to Oversee Clinical Development

Retrieved on: 
Tuesday, July 19, 2022

New York, July 19, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI) driven drug discovery company, has appointed Dr. Sujata Rao as Senior Vice President (SVP) with responsibility for the global clinical development strategy of Insilico Medicine's therapeutic programs.

Key Points: 
  • New York, July 19, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI) driven drug discovery company, has appointed Dr. Sujata Rao as Senior Vice President (SVP) with responsibility for the global clinical development strategy of Insilico Medicine's therapeutic programs.
  • The unique opportunity at Insilico allows me to join a world class AI drug discovery team that can rapidly bring novel drugs to patients with a great unmet need, said Sujata Rao M.D., Senior Vice President, Head of Clinical Development at Insilico Medicine.
  • This is a transformative approach to drug development with shortened timelines that I hope will make a huge clinical impact.
  • Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems.

Advanced Hepatocellular Carcinoma Pipeline Market Research Report 2022: Comprehensive Insights about 50+ Companies and 50+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Monday, May 30, 2022

This "Advanced Hepatocellular Carcinoma- Pipeline Insight, 2022" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced Hepatocellular Carcinoma pipeline landscape.

Key Points: 
  • This "Advanced Hepatocellular Carcinoma- Pipeline Insight, 2022" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced Hepatocellular Carcinoma pipeline landscape.
  • "Advanced Hepatocellular Carcinoma- Pipeline Insight, 2022" report outlays comprehensive insights of present scenario and growth prospects across the indication.
  • A detailed picture of the Advanced Hepatocellular Carcinoma pipeline landscape is provided which includes the disease overview and Advanced Hepatocellular Carcinoma treatment guidelines.
  • The assessment part of the report embraces, in depth Advanced Hepatocellular Carcinoma commercial assessment and clinical assessment of the pipeline products under development.

Innovent Will Present Clinical Data of IBI110 (anti-LAG-3 monoclonal antibody) and Other Multiple Trials at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Monday, May 16, 2022

Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic, ophthalmologyand other major diseases.

Key Points: 
  • Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic, ophthalmologyand other major diseases.
  • On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
  • Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
  • Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts.

HUTCHMED Highlights Fruquintinib Clinical Data to be Presented at the 2022 ASCO Gastrointestinal Cancers Symposium

Retrieved on: 
Wednesday, January 19, 2022

Fruquintinib was designed to improve kinase selectivity to minimize off-target toxicities, improve tolerability and provide more consistent target coverage.

Key Points: 
  • Fruquintinib was designed to improve kinase selectivity to minimize off-target toxicities, improve tolerability and provide more consistent target coverage.
  • It was included in the China National Reimbursement Drug List (NRDL) in January 2020.
  • Patients are randomized at a 1:1 ratio and stratified according to factors such as stomach vs. GEJ tumor type and performance status.
  • Preliminary results of certain cohorts were presented at the 2021 American Society of Clinical Oncology Annual Meeting (ASCO) and the Chinese Society of Clinical Oncology Annual Meeting (CSCO).

Adimab Provides 2021 Update on Clinical Pipeline

Retrieved on: 
Wednesday, January 19, 2022

In 2021, Innovent and Lilly filed a BLA with the FDA for approval in the United States.

Key Points: 
  • In 2021, Innovent and Lilly filed a BLA with the FDA for approval in the United States.
  • In 2021, Adimab partners exercised 10 commercial licenses to advance programs into development, bringing the total number of optioned programs to more than 85.
  • Adimab focuses solely on its partners and not on developing an internal product pipeline.
  • Since 2009, Adimab has partnered with 95 pharmaceutical and biotechnology companies, generating 425 therapeutic programs, 55 clinical programs, and its first approved product.

HUTCHMED Highlights Oral Presentations at 2021 Chinese Society of Clinical Oncology Annual Meeting

Retrieved on: 
Wednesday, September 29, 2021

In first-line clear-cell renal cell carcinoma (ccRCC), clinical benefits have been demonstrated for the combination of antiangiogenic therapy and immunotherapy.

Key Points: 
  • In first-line clear-cell renal cell carcinoma (ccRCC), clinical benefits have been demonstrated for the combination of antiangiogenic therapy and immunotherapy.
  • As of data cutoff date of August 31, 2021, all 20 enrolled patients were efficacy evaluable.
  • The confirmed ORR was 55.0% (95% CI: 31.5-76.9) and DCR was 85.0% (95% CI: 62.1-96.8).
  • The median PFS was not reached with a median follow up of 8.2 months.